Rosenberg Matthew Hamilton Amgen Inc Transaction History

Rosenberg Matthew Hamilton

$378 Million
Q3 2024

A detailed history of Rosenberg Matthew Hamilton transactions in Amgen Inc stock. As of the latest transaction made, Rosenberg Matthew Hamilton holds 912 shares of AMGN stock, worth $268,611. This represents 0.08% of its overall portfolio holdings.

Number of Shares

912

Previous 912 -0.0%

Holding current value

$268,611

Previous $284,000 3.17%

% of portfolio

0.08%

Previous 0.08%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 26, 2024	BUY	$262.75 - $319.31 $14,976 - $18,200	57 Added 6.67%	912 $284,000
Q1 2024 Apr 19, 2024	BUY	$268.87 - $324.56 $6,452 - $7,789	24 Added 2.89%	855 $243,000
Q4 2023 Jan 12, 2024	BUY	$255.7 - $288.46 $9,460 - $10,673	37 Added 4.66%	831 $239,000
Q3 2023 Oct 11, 2023	SELL	$218.65 - $271.46 $17,492 - $21,716	-80 Reduced 9.15%	794 $213,000
Q2 2023 Jul 26, 2023	SELL	$214.27 - $253.37 $34,497 - $40,792	-161 Reduced 15.56%	874 $194,000
Q1 2023 Apr 17, 2023	BUY	$225.79 - $275.2 $4,741 - $5,779	21 Added 2.07%	1,035 $250,000
Q4 2022 Jan 18, 2023	BUY	$229.03 - $291.01 $15,574 - $19,788	68 Added 7.19%	1,014 $0
Q3 2022 Oct 21, 2022	BUY	$224.46 - $253.15 $7,856 - $8,860	35 Added 3.84%	946 $213,000
Q4 2021 Jan 20, 2022	BUY	$198.88 - $227.6 $50,714 - $58,038	255 Added 38.87%	911 $205,000
Q3 2021 Oct 12, 2021	BUY	$212.27 - $248.7 $21,227 - $24,870	100 Added 17.99%	656 $139,000
Q4 2020 Feb 03, 2021	BUY	$216.38 - $257.67 $10,819 - $12,883	50 Added 9.88%	556 $128,000
Q2 2020 Aug 04, 2020	BUY	$197.81 - $242.74 $12,857 - $15,778	65 Added 14.74%	506 $119,000
Q1 2020 May 14, 2020	BUY	$182.24 - $241.7 $80,367 - $106,589	441 New	441 $90,000

Others Institutions Holding AMGN

# of Institutions

3,122

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $158B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rosenberg Matthew Hamilton, based on Form 13F filings with the SEC.

News

Stay updated on Rosenberg Matthew Hamilton with notifications on news.

Account

Rosenberg Matthew Hamilton Amgen Inc Transaction History